Head and neck cancer support and awareness
  • Home
  • About Us
    • Messages from our CEO and President
    • List of Officers and Board of Directors
    • Our Beginnings
    • Gallery
    • Contact Us
  • Meetings & Support
    • Support Programs
    • Our Support Group
    • Fundraisers & Events
  • Information
    • Helpful Tips
      • What to Say to a Cancer Survivor
      • Swallowing Tips
      • Dry Mouth
    • Links & Resources
    • Are you a caregiver? We’re here for you!
    • Research
    • Recipes & Recipe Books
  • Inspiring Stories
    • Alicia Currin’s Story
    • Joe Lapides’ Story
    • Willie Tusan, Jr’s Journey
    • The Dave Hixson Story
    • The Althea Tymony Story
    • The Gary Uline Story (In his own words)
    • Gary’s Story, told by Paula, his wife
    • Larry Gallagher’s Survivor’s Story, January 2015
    • “Stones Along the Road” – by Robert Kinaga, 2008
    • Beginning Recovery Inspired Mark Phair to Complete the Ironman
    • The Blair Franks Story – From Surgery to Walking his Daughter Down The Aisle
  • Blog
  • Make a Donation

A 501(c)(3) Non-Profit Corporation Advocating Health Issues for Head and Neck Cancer Patients

March 3, 2019

FDA approves expanded use of Gardasil 9

HNC Support Blog, Home, News & Articles

FDA approves expanded use of Gardasil 9 to include individuals 27 through 45 years old

The U.S. Food and Drug Administration today approved a supplemental application for Gardasil 9 (Human Papillomavirus (HPV) 9-valent Vaccine, Recombinant) expanding the approved use of the vaccine to include women and men aged 27 through 45 years. Gardasil 9 prevents certain cancers and diseases caused by the nine HPV types covered by the vaccine.

“Today’s approval represents an important opportunity to help prevent HPV-related diseases and cancers in a broader age range,” said Peter Marks, M.D., Ph.D., director of the FDA’s Center for Biologics Evaluation and Research. ”The Centers for Disease Control and Prevention has stated that HPV vaccination prior to becoming infected with the HPV types covered by the vaccine has the potential to prevent more than 90 percent of these cancers, or 31,200 cases every year, from ever developing.”

According to the CDC, every year about 14 million Americans become infected with HPV; about 12,000 women are diagnosed with and about 4,000 women die from cervical cancer caused by certain HPV viruses. Additionally, HPV viruses are associated with several other forms of cancer affecting men and women.

Gardasil, a vaccine approved by the FDA in 2006 to prevent certain cancers and diseases caused by four HPV types, is no longer distributed in the U.S. In 2014, the FDA approved Gardasil 9, which covers the same four HPV types as Gardasil, as well as an additional five HPV types. Gardasil 9 was approved for use in males and females aged 9 through 26 years.

The effectiveness of Gardasil is relevant to Gardasil 9 since the vaccines are manufactured similarly and cover four of the same HPV types. In a study in approximately 3,200 women 27 through 45 years of age, followed for an average of 3.5 years, Gardasil was 88 percent effective in the prevention of a combined endpoint of persistent infection, genital warts, vulvar and vaginal precancerous lesions, cervical precancerous lesions, and cervical cancer related to HPV types covered by the vaccine. The FDA’s approval of Gardasil 9 in women 27 through 45 years of age is based on these results and new data on long term follow-up from this study.

Effectiveness of Gardasil 9 in men 27 through 45 years of age is inferred from the data described above in women 27 through 45 years of age, as well as efficacy data from Gardasil in younger men (16 through 26 years of age) and immunogenicity data from a clinical trial in which 150 men, 27 through 45 years of age, received a 3-dose regimen of Gardasil over 6 months.

The safety of Gardasil 9 was evaluated in about a total of 13,000 males and females. The most commonly reported adverse reactions were injection site pain, swelling, redness and headaches.

The FDA granted the Gardasil 9 application priority review status. This program facilitates and expedites the review of medical products that address a serious or life-threatening condition. 

The FDA granted approval of this supplement to the Gardasil 9 Biologics License Application to Merck, Sharp & Dohme Corp. a subsidiary of Merck & Co., Inc.

The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.

Source: https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm622715.htm

The Benefits of Turmeric and Honey Guest Speaker at the October HNC Support Group

Related Posts

The Alien Has To Go, by Alison Pywell

Blog, Home, Recommended Books

The Alien Has To Go, by Alison Pywell

A Survey to help researchers at Rush University

Blog, Home

A Survey to help researchers at Rush University

Nicole, 28, from California, found her toothache was actually a tumor. Please read her story

Blog, Home, Patient Story, Treatment and Recovery

Nicole, 28, from California, found her toothache was actually a tumor. Please read her story

Lend Your Support

Help support our efforts by making a donation. Your donation to HNC Support will make a difference in the lives of real people who are struggling to overcome severe health issues.  Any amount will help!

Donate Today

Shop & Support HNC

When you shop at AmazonSmile, Amazon donates 0.5% of the purchase price to HNC Support International.

Bookmark this link and support us every time you shop.

HNC Support International

Support Group

HNC support group:
February 6th PST Register here

Caregivers support group:
January 23rd 10am PST Register here

For more information, registration links, and more, visit & bookmark our support groups page.

HNC Support International Inc

Mailing Address

HNC Support International, INC.
68 Penhill Court
Glendale, CA. 91206 USA

Email us
Contact our caregivers

Support group

Keck Hospital
1500 San Pablo St,
Los Angeles, CA 90033
Cardinal conference room on 1st floor

Map & directions

IMPORTANT Click to read notice regarding our support group meetings.

Browse our site

  • Home
  • About Us
  • Support Group Meetings
  • Stories of Survival
  • Information
  • Blog
  • Gallery
  • Caregivers
  • Make a Donation
  • Contact Us

Please Note: The products/activities/items mentioned on this site should not be misconstrued to be professional medical advice. Anything referenced should not be considered a recommendation or attest to that products effectiveness. We highly advise everyone to talk to their own doctor before seeking treatment or reaching a conclusion on any product or activity. Treat this web site as lay and informational only --- and NOT as a substitute for prudent professional medical counsel.

A 501(c)(3) Non-Profit Corporation Advocating Health Issues for Head and Neck Cancer Patients


Copyright 2021 HNC Support International INC.,


Designed by: Virtue Media